Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug;135(Pt 8):2440-8.
doi: 10.1093/brain/aws174.

The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow

Affiliations

The neurobiology of glucocerebrosidase-associated parkinsonism: a positron emission tomography study of dopamine synthesis and regional cerebral blood flow

Ozlem Goker-Alpan et al. Brain. 2012 Aug.

Abstract

Mutations in GBA, the gene encoding glucocerebrosidase, the enzyme deficient in Gaucher disease, are common risk factors for Parkinson disease, as patients with Parkinson disease are over five times more likely to carry GBA mutations than healthy controls. Patients with GBA mutations generally have an earlier onset of Parkinson disease and more cognitive impairment than those without GBA mutations. We investigated whether GBA mutations alter the neurobiology of Parkinson disease, studying brain dopamine synthesis and resting regional cerebral blood flow in 107 subjects (38 women, 69 men). We measured dopamine synthesis with (18)F-fluorodopa positron emission tomography, and resting regional cerebral blood flow with H(2)(15)O positron emission tomography in the wakeful, resting state in four study groups: (i) patients with Parkinson disease and Gaucher disease (n = 7, average age = 56.6 ± 9.2 years); (ii) patients with Parkinson disease without GBA mutations (n = 11, 62.1 ± 7.1 years); (iii) patients with Gaucher disease without parkinsonism, but with a family history of Parkinson disease (n = 14, 52.6 ± 12.4 years); and (iv) healthy GBA-mutation carriers with a family history of Parkinson disease (n = 7, 50.1 ± 18 years). We compared each study group with a matched control group. Data were analysed with region of interest and voxel-based methods. Disease duration and Parkinson disease functional and staging scores were similar in the two groups with parkinsonism, as was striatal dopamine synthesis: both had greatest loss in the caudal striatum (putamen Ki loss: 44 and 42%, respectively), with less reduction in the caudate (20 and 18% loss). However, the group with both Parkinson and Gaucher diseases showed decreased resting regional cerebral blood flow in the lateral parieto-occipital association cortex and precuneus bilaterally. Furthermore, two subjects with Gaucher disease without parkinsonian manifestations showed diminished striatal dopamine. In conclusion, the pattern of dopamine loss in patients with both Parkinson and Gaucher disease was similar to sporadic Parkinson disease, indicating comparable damage in midbrain neurons. However, H(2)(15)O positron emission tomography studies indicated that these subjects have decreased resting activity in a pattern characteristic of diffuse Lewy body disease. These findings provide insight into the pathophysiology of GBA-associated parkinsonism.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Ki values. Parametric comparison of Parkinson disease groups with their respective control groups. Colour bar indicates t values. Displayed at height threshold T = 6.26 (P < 0.001 family-wise error-corrected) to highlight areas of greatest contrast. Dopamine synthesis is decreased mainly in the tail of the putamen, with a similar distribution in both groups. GD = Gaucher disease; PD = Parkinson disease.
Figure 2
Figure 2
Ki values. Parametric comparison of patients with Gaucher disease without parkinsonism and their controls. On the SPM ‘glass brains’ (left) and on a standard single subject template (right), striatal regions where the group of patients with Gaucher disease but no clinical manifestations of parkinsonism had lower Ki values than their control group (Table 3). PD = Parkinson disease.
Figure 3
Figure 3
Regional cerebral blood flow in the group with both Parkinson and Gaucher diseases group compared with its control group. Regions with lower regional cerebral blood flow in the group with Parkinson and Gaucher diseases (Table 3), displayed on a rendered template in A and on a midsagittal section of a standard brain in B. Note that the precuneus is involved, but the posterior cingulate, indicated by the arrow in B, is not (‘cingulate island’ sign).

Similar articles

Cited by

References

    1. Alcalay RN, Caccappolo E, Mejia-Santana H, Tang MX, Rosado L, Orbe Reilly M, et al. Cognitive performance of GBA mutation carriers with early-onset PD: the CORE-PD study. Neurology. 2012;78:1434–40. - PMC - PubMed
    1. Bharucha NE, Stokes L, Schoenberg BS, Ward C, Ince S, Nutt JG, et al. A case-control study of twin pairs discordant for Parkinson disease: a search for environmental risk factors. Neurology. 1986;36:284–8. - PubMed
    1. Brockmann K, Srulijes K, Hauser AK, Schulte C, Csoti I, Gasser T, et al. GBA-associated PD presents with nonmotor characteristics. Neurology. 2011;77:276–80. - PubMed
    1. Compta Y, Parkkinen L, O’Sullivan SS, Vandrovcova J, Holton JL, Collins C, et al. Lewy- and Alzheimer-type pathologies in Parkinson disease dementia: which is more important? Brain. 2011;134:1493–505. - PMC - PubMed
    1. Elbaz A, Bower JH, Maraganore DM, McDonnell SK, Peterson BJ, Ahlskog JE, et al. Risk tables for parkinsonism and Parkinson disease. J Clin Epidemiol. 2002;55:25–31. - PubMed

Publication types